Khatora S. Opperman

Khatora S. Opperman

Auto-generated profile, based on publicly available information

Khatora S. Opperman

Myeloma Research Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, North Terrace, Adelaide, SA 5005, Australia; South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA 5001, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2019 in Blood
Verified
Journal Article
Closed access
PDF file
WKWeng Hua Khoo
Weng Hua Khoo
GLGuy Ledergor
Guy Ledergor
AWAssaf Weiner
Assaf Weiner
DRDaniel L. Roden
Daniel L. Roden
Rachael Louise TerryRachael Louise Terry
Rachael Louise Terry
PCPeter I. Croucher
Peter I. Croucher
The era of targeted therapies has seen significant improvements in depth of response, progression-free survival, and overall survival for patients with multiple myeloma. Despite these improvements in clinical outcome, patients inevitably relapse and require further treatment. Drug-resistant dormant myeloma cells that reside in specific niches within the skeleton are considered a basis of disease relapse but remain elusive and difficult to study. Here, we developed a method to sequence the transcriptome of individual dormant myeloma cells from the bones of tumor-bearing mice. Our analyses show that dormant myeloma cells express a distinct transcriptome signature enriched for immune genes and, unexpectedly, genes associated with myeloid cell differentiation. These genes were switched on by coculture with osteoblastic cells. Targeting AXL, a gene highly expressed by dormant cells, using small-molecule inhibitors released cells from dormancy and promoted their proliferation. Analysis of the expression of AXL and coregulated genes in human cohorts showed that healthy human controls and patients with monoclonal gammopathy of uncertain significance expressed higher levels of the dormancy signature genes than patients with multiple myeloma. Furthermore, in patients with multiple myeloma, the expression of this myeloid transcriptome signature translated into a twofold increase in overall survival, indicating that this dormancy signature may be a marker of disease progression. Thus, engagement of myeloma cells with the osteoblastic niche induces expression of a suite of myeloid genes that predicts disease progression and that comprises potential drug targets to eradicate dormant myeloma cells.

1 August 2019 in Neoplasia
Verified
Journal Article
Open access
KOKhatora S. Opperman
Khatora S. Opperman
KVKate Vandyke
Kate Vandyke
KCKimberley Clark
Kimberley Clark
ECElizabeth A. Coulter
Elizabeth A. Coulter
DHDuncan R. Hewett
Duncan R. Hewett
AZAndrew Zannettino
Andrew Zannettino
Multiple myeloma is a fatal plasma cell malignancy that is reliant on the bone marrow microenvironment. The bone marrow is comprised of numerous cells of mesenchymal and hemopoietic origin. Of these, macrophages have been implicated to play a role in myeloma disease progression, angiogenesis, and drug resistance; however, the role of macrophages in myeloma disease establishment remains unknown. In this study, the antimyeloma efficacy of clodronate-liposome treatment, which globally and transiently depletes macrophages, was evaluated in the well-established C57BL/KaLwRijHsd murine model of myeloma. Our studies show, for the first time, that clodronate-liposome pretreatment abrogates myeloma tumor development in vivo. Clodronate-liposome administration resulted in depletion of CD169+ bone marrow-resident macrophages. Flow cytometric analysis revealed that clodronate-liposome pretreatment impaired myeloma plasma cell homing and retention within the bone marrow 24 hours postmyeloma plasma cell inoculation. This was attributed in part to decreased levels of macrophage-derived insulin-like growth factor 1. Moreover, a single dose of clodronate-liposome led to a significant reduction in myeloma tumor burden in KaLwRij mice with established disease. Collectively, these findings support a role for CD169-expressing bone marrow-resident macrophages in myeloma disease establishment and progression and demonstrate the potential of targeting macrophages as a therapy for myeloma patients.

1 November 2021 in Cell Reports
Verified
Journal Article
Open access
SMSusan M. Millard
Susan M. Millard
OHOstyn Heng
Ostyn Heng
KOKhatora S. Opperman
Khatora S. Opperman
ASAnuj Sehgal
Anuj Sehgal
KIKatharine Irvine
Katharine Irvine
APAllison R. Pettit
Allison R. Pettit
Mouse hematopoietic tissues contain abundant tissue-resident macrophages that support immunity, hematopoiesis, and bone homeostasis. A systematic strategy to characterize macrophage subsets in mouse bone marrow (BM), spleen, and lymph node unexpectedly reveals that macrophage surface marker staining emanates from membrane-bound subcellular remnants associated with unrelated cells. Intact macrophages are not present within these cell preparations. The macrophage remnant binding profile reflects interactions between macrophages and other cell types in vivo. Depletion of CD169+ macrophages in vivo eliminates F4/80+ remnant attachment. Remnant-restricted macrophage-specific membrane markers, cytoplasmic fluorescent reporters, and mRNA are all detected in non-macrophage cells including isolated stem and progenitor cells. Analysis of RNA sequencing (RNA-seq) data, including publicly available datasets, indicates that macrophage fragmentation is a general phenomenon that confounds bulk and single-cell analysis of disaggregated hematopoietic tissues. Hematopoietic tissue macrophage fragmentation undermines the accuracy of macrophage ex vivo molecular profiling and creates opportunity for misattribution of macrophage-expressed genes to non-macrophage cells.

6 January 2021 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
KOKhatora S. Opperman
Khatora S. Opperman
KVKate Vandyke
Kate Vandyke
PPPeter J. Psaltis
Peter J. Psaltis
JNJacqueline E. Noll
Jacqueline E. Noll
AZAndrew Zannettino
Andrew Zannettino

28 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSusan M Millard
Susan M Millard
OHOstyn Heng
Ostyn Heng
KOKhatora S Opperman
Khatora S Opperman
ASAnuj Sehgal
Anuj Sehgal
KIKatharine Irvine
Katharine Irvine
APAllison R Pettit
Allison R Pettit
Summary: Mouse hematopoietic tissues contain abundant and heterogeneous populations of tissue-resident macrophages attributed trophic functions in control of immunity, hematopoiesis and bone homeostasis. A systematic strategy to characterise macrophage subsets in mouse bone marrow (BM), spleen and lymph node, unexpectedly revealed macrophage surface marker staining typically emanated from membrane-bound subcellular remnants associated with unrelated cell types. Remnant-restricted macrophage-specific membrane markers, cytoplasmic fluorescent reporters and mRNA were all detected in non-macrophage cell populations including isolated stem and progenitor cells. The profile of macrophage remnant association reflects adhesive interactions between macrophages and other cell types in vivo. Applying this knowledge, reduced macrophage remnant attachment to BM granulocytes in Siglec1 deficient mice was associated with compromised emergency granulocytosis, revealing a function for Siglec1 -dependent granulocyte-macrophage interactions. Analysis of published RNA-seq data for purified macrophage and non-macrophage populations indicates that macrophage fragmentation is a general phenomenon that confounds bulk and single cell analysis of disaggregated tissues.

1 October 2019 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
KOKhatora Opperman
Khatora Opperman
KVKate Vandyke
Kate Vandyke
PPPeter Psaltis
Peter Psaltis
PCPeter Croucher
Peter Croucher
JNJacqueline Noll
Jacqueline Noll
AZAndrew Zannettino
Andrew Zannettino